Because MLX01 reduces IL-1B secretion but not transcription (Figure S2B–D), we used ELISA (Figure S2D) to first confirm that oral gavage of 100 mg/kg MLX01 reduced IL-1B secretion in mice to the same level as administering 50 mg/kg via i.p injection (Figure S2B,C) Oral gavage of 100mg/kg MLX01 reduced the number of overt metastases of whole mice (p = 0.0085) and reduced metastatic outgrowth of E0771 cells in the bone by 50% and 34%, 10 days and 16 days after tumour cell injection, respectively (Figure S6C,E). This evidence concerns the gene IL1B and neoplasm.